Study title:
A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi
Long title:
A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination with ALVAC-HIV (vCP-1452) and Remune or placebo while maintaining optimal therapeutic viral suppression
Date receipt dossier:
13 Oct 2000
Pharmaceutical study code:
PROB3005
Company / Sponsor:
Glaxo Wellcome
Phase:
III
Treated organism:
Humans
Indication category:
Infectious disease
Disease:
AIDS
Therapeutic approach:
Immunotherapy
Genetic modification:
vCP-1452
Method of transfer of nucleic acid of interest:
Attenuated Canarypox Virus (ALVAC)
Administered biological material:
Recombinant Canarypox Virus
Route of administration:
Intramuscular
Locations in Belgium:
Centre Hospitalier Universitaire St Pierre, Brussels
Type of procedure:
Contained use only
Notes:
Sponsor of the study: Glaxo Wellcome; Manufacturer of the GMO: Aventis-Pasteur S.A.